Evogene Ltd. (NASDAQ:EVGN) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positive developments, such as the acquisition of Lavie Bio by ICL and reduced expenses, there are concerns over declining revenues, operational risks, and funding challenges. The Q&A session highlights management's reluctance to provide clear guidance, raising uncertainties. Despite reduced expenses and a cash inflow from asset sales, the reliance on subsidiaries for revenue and the lack of clarity on future orders temper optimism. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
Key Financial Performance
Total Revenues $2.4 million (decrease of approximately 43% year-over-year from $4.2 million); decrease primarily due to $3.5 million in license fee payments recognized in Q1 2024 from Lavie Bio and AgPlenus.
Total R&D Expenses $3.2 million (decrease of approximately 33% year-over-year from $4.8 million); decrease mainly due to reduced R&D activity in Biomica and Lavie Bio, and closure of Canonic's operations.
Total Sales and Marketing Expenses $0.6 million (decrease of approximately 35% year-over-year from $1 million); decrease primarily due to reduced sales and marketing activity in Lavie Bio.
Total Operating Expenses Net $5 million (decrease of approximately 38% year-over-year from $8 million); decrease mainly due to reduced operating activity in Lavie Bio and Biomica.
Cash and Short-term Bank Deposits $9.8 million (decrease from $15.3 million as of December 31, 2024); cash balance does not reflect $2 million due from Casterra's outstanding customers.
Net Loss $3 million (decrease of approximately 21% year-over-year from $3.8 million); decrease primarily due to reduced operating expenses and increased net financing income.
Net Financing Income $1.5 million (compared to net financing income of approximately $241,000 in the same period last year); increase due to accounting treatment of pre-funded warrants and warrants issued in August 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ChemPass-AI for pharma: Refined value proposition for pharmaceutical and biotech sectors, focusing on designing novel compounds.
BMC128: Phase I clinical study shows early signs of effectiveness through immune activation.
New mode of action for fungicides: AgPlenus discovered a new mode of action for fungicides against Septoria in wheat.
Casterra seed sales: Casterra delivered 250 tons of castor seeds to Africa, surpassing 2024's total.
Lavie Bio acquisition: ICL to acquire Lavie Bio's activities for $15.25 million, expected to close in Q2 2025.
MicroBoost AI sale: ICL to acquire MicroBoost AI tech-engine for approximately $3.5 million.
Expense reduction plan: Evogene established an expense reduction plan expected to be completed by Q2 2025.
R&D expenses: R&D expenses decreased to $3.2 million from $4.8 million year-over-year.
Sales and marketing expenses: Sales and marketing expenses decreased to $0.6 million from $1 million year-over-year.
Focus on ChemPass-AI: Evogene aims to enhance ChemPass-AI for drug discovery and develop a capital-efficient model.
Exit events for subsidiaries: Evogene is focusing on creating exit events for subsidiaries to generate value and cash.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geopolitical Risks: The ongoing war between Israel, Hamas, and Hezbollah poses significant risks to Evogene's operations, particularly if the situation escalates further.
Regulatory Risks: The acquisition of Lavie Bio by ICL is subject to customary and regulatory closing conditions, which may introduce delays or complications.
Financial Risks: Evogene's cash balance has decreased from approximately $15.3 million to $9.8 million, indicating potential liquidity challenges. Additionally, the company reported a significant decline in revenues from $4.2 million to $2.4 million, primarily due to the absence of prior license fee payments.
Operational Risks: The closure of Canonic's operations has resulted in additional expenses and may impact overall operational efficiency.
Funding Risks: Biomica requires additional funding to advance to Phase II of its clinical study for BMC128, which may pose challenges in securing necessary financial resources.
Market Risks: Evogene's revenue generation is heavily reliant on its subsidiaries, and any underperformance in these areas could adversely affect overall financial health.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Expense Reduction Plan: Evogene established an expense reduction plan, which will be completed by the second quarter of 2025, already partially reflected in Q1 2025 results.
Acquisition of Lavie Bio by ICL: Evogene announced the acquisition of most of Lavie Bio's activities by ICL for an aggregate value of $15.25 million, expected to close in Q2 2025.
Casterra Seed Sales: Casterra delivered 250 tons of castor seeds to its partner in Africa, surpassing the total of 215 tons delivered in 2024.
AgPlenus Discovery: AgPlenus announced the discovery of a new mode of action for fungicides against Septoria in wheat, with plans to engage potential licensing partners by year-end.
Biomica Phase I Study: Biomica's Phase I clinical study of BMC128 is progressing, with early signs of effectiveness observed within 14 days of treatment.
Revenue Expectations: Total revenues for Q1 2025 were approximately $2.4 million, down from $4.2 million in Q1 2024, primarily due to a lack of license fee payments.
Future Cash Flow: Expected proceeds from the sale of Lavie Bio’s assets and MicroBoost AI tech-engine to ICL, anticipated to close in Q2 2025.
Funding for Biomica: Additional funding is necessary for Biomica to advance to Phase II of the clinical study for BMC128.
Sales Strategy for Casterra: Casterra has initiated proof-of-concept trials for grain cultivation in Kenya and Brazil, with expected initial results in Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Acquisition of Lavie Bio by ICL: On April 21, 2025, Evogene announced the acquisition of most of Lavie Bio’s activity and assets by ICL for an aggregate value of $15.25 million. Additionally, ICL will acquire Evogene’s MicroBoost AI tech-engine for approximately $3.5 million. This transaction is expected to generate value for Evogene through direct sales and potential future dividends as Evogene remains a major shareholder in Lavie Bio.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:With the 250 tons of castor seeds delivered in the first quarter, does this complete the initial order from any place in mid-2023 or do you expect additional sales from this order later this year?
A:Yes, we are still waiting to receive additional orders for this year. We have a nice quantity of inventory that we can deliver if we receive orders.
Q:Do you expect a follow on order to be an increase or decrease?
A:I can’t disclose much because it reflects what’s going on in our partner activity, but the interest in castor is growing.
Q:What is the net cash inflow Evogene will be receiving from the ICL for the Lavie Bio transaction?
A:We will receive $3.5 million from selling Evogene MicroBoost for Ag, and Lavie Bio will receive $15.25 million.
Q:Casterra sales were strong in the first quarter of 2025. How should we think about the rest of 2025 and what should the cadence look like?
A:I can’t give a projection because it depends on the performance of our partners.
Q:At close of asset sale, how much cash will you receive?
A:I already answered this question that was asked by Ben Klieve.
Q:What are the customary closing conditions for the ICL deal? Is there any danger for not closing the agreement?
A:We don’t see any reason why we won’t be able to close the deal.
Q:Combining this with reduced expenses, how should we be thinking about the strength of the balance sheet for the foreseeable future in terms of duration?
A:We are safe from a financial perspective till the end of 2026, assuming a very conservative analysis.
Q:Of the $18.75 million consideration in selling Lavie Bio assets, what net cash to the parent was realized?
A:I already answered this in response to Ben Klieve's question.
Q:What happened to the narrative that there would be multiple oil companies lining up to buy castor seeds to replace palm oil as the biodegradable component in diesel fuel?
A:Currently, we don’t see this approach adopted by additional oil companies.
Q:With your reduced expenses, how long will the cash last for you?
A:I feel quite comfortable till the end of 2026 assuming a conservative approach.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to questions regarding the follow-on order expectations, the net cash from the Lavie Bio transaction, and the narrative about oil companies buying castor seeds.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Ag
AI tech
AgPlenus
Biomica
Brazil
ChemPass AI
ChemPass GPT
MicroBoost AI
Phase
Septoria
achievement
acquisition
activity
candidate
castor
collaboration
compound
decrease
drug discovery
effort
end
event
expectation
field
mode
model
molecule
optimization
parameter
partner
plan
product
reduction
sale
seed
solution
study
subsidiary
tech engine
transaction ICL
EVGN Transcript
Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call reveals declining revenues, increased costs, and significant operating and net losses, indicating financial struggles. Despite cost reductions, the lack of clear guidance and vague responses during the Q&A, particularly regarding financial terms and timelines, adds uncertainty. The promising strategic shifts and partnerships, including with Google, are overshadowed by the immediate financial challenges. The market is likely to react negatively in the short term due to these concerns, leading to a predicted stock price movement in the negative range of -2% to -8%.
Evogene Ltd. (EVGN) Q3 2025 Earnings Call Transcript
Positive11-20
The earnings call reveals a mixed but overall positive sentiment. Financial performance shows improvement in net loss and operating loss, though revenues slightly decreased. The AI ChemPass platform is gaining interest, with potential partnerships on the horizon. Management's enthusiasm for AI ChemPass and planned IR activities could boost investor confidence. Despite some unclear responses in the Q&A, the focus on strategic partnerships and financial health supports a positive outlook for stock price movement.
Evogene Ltd. (EVGN) Q2 2025 Earnings Call Transcript
Positive8-19
The earnings call highlights strong revenue growth, significant reductions in operating expenses, and promising developments in castor seed sales and field trials. The Q&A section reveals optimism about future collaborations and advancements, particularly in the ChemPass AI platform. Despite some vague responses, the focus on new strategies and partnerships suggests a positive outlook. The financial improvements and strategic plans indicate a likely stock price increase of 2% to 8% over the next two weeks.
Evogene Ltd. (NASDAQ:EVGN) Q1 2025 Earnings Call Transcript
Unknown5-22
The earnings call presents a mixed picture. While there are positive developments, such as the acquisition of Lavie Bio by ICL and reduced expenses, there are concerns over declining revenues, operational risks, and funding challenges. The Q&A session highlights management's reluctance to provide clear guidance, raising uncertainties. Despite reduced expenses and a cash inflow from asset sales, the reliance on subsidiaries for revenue and the lack of clarity on future orders temper optimism. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
EVGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
